481 related articles for article (PubMed ID: 37990309)
1. A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma.
Han X; Liang L; He C; Ren Q; Su J; Cao L; Zheng J
BMC Complement Med Ther; 2023 Nov; 23(1):422. PubMed ID: 37990309
[TBL] [Abstract][Full Text] [Related]
2. Understanding apoptotic induction by Sargentodoxa cuneata-Patrinia villosa herb pair via PI3K/AKT/mTOR signalling in colorectal cancer cells using network pharmacology and cellular studies.
Mu BX; Li Y; Ye N; Liu S; Zou X; Qian J; Wu C; Zhuang Y; Chen M; Zhou JY
J Ethnopharmacol; 2024 Jan; 319(Pt 3):117342. PubMed ID: 37879505
[TBL] [Abstract][Full Text] [Related]
3. [Mechanism of n-butanol fraction of Wenxia Formula combining with gefitinib in treating non-small cell lung cancer based on network pharmacology and in vitro experiment].
Chen RJ; Bi QY; Shi JM; Zhong J; Han JT; Ji XM
Zhongguo Zhong Yao Za Zhi; 2024 Jan; 49(2):471-486. PubMed ID: 38403323
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of Bazhen decoction in the treatment of colorectal cancer based on network pharmacology, molecular docking, and experimental validation.
Lu S; Sun X; Zhou Z; Tang H; Xiao R; Lv Q; Wang B; Qu J; Yu J; Sun F; Deng Z; Tian Y; Li C; Yang Z; Yang P; Rao B
Front Immunol; 2023; 14():1235575. PubMed ID: 37799727
[TBL] [Abstract][Full Text] [Related]
5. [STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma].
Huang L; Hou M; Liu J; Li Y; Shen W; Zhou Q
Zhongguo Fei Ai Za Zhi; 2022 Nov; 25(11):771-781. PubMed ID: 36419390
[TBL] [Abstract][Full Text] [Related]
6. Molecular and metabolic mechanisms of bufalin against lung adenocarcinoma: New and comprehensive evidences from network pharmacology, metabolomics and molecular biology experiment.
Shi S; Zhao S; Tian X; Liu F; Lu X; Zang H; Li F; Xiang L; Li L; Jiang S
Comput Biol Med; 2023 May; 157():106777. PubMed ID: 36924737
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of Key Ingredient of Astragalus membranaceus on Lung Adenocarcinoma via PI3K/AKT Signaling Clarified by Utilizing Network Pharmacology Approach and Experimental Validation.
Wang YC; Hui JR; Xiao G; Ma QL
Chin J Integr Med; 2023 Mar; 29(3):244-252. PubMed ID: 36044117
[TBL] [Abstract][Full Text] [Related]
8. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
Lu GS; Li M; Xu CX; Wang D
Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
[TBL] [Abstract][Full Text] [Related]
9. Investigate the mechanisms of Chinese medicine Fuzhengkangai towards EGFR mutation-positive lung adenocarcinomas by network pharmacology.
Bing Z; Cheng Z; Shi D; Liu X; Tian J; Yao X; Zhang J; Wang Y; Yang K
BMC Complement Altern Med; 2018 Nov; 18(1):293. PubMed ID: 30400936
[TBL] [Abstract][Full Text] [Related]
10. Construction of a circRNA-miRNA-mRNA Regulated Pathway Involved in EGFR-TKI Lung Adenocarcinoma Resistance.
Dai C; Liu B; Li S; Hong Y; Si J; Xiong Y; Wu N; Ma Y
Technol Cancer Res Treat; 2021; 20():15330338211056809. PubMed ID: 34825849
[No Abstract] [Full Text] [Related]
11. Efficacy of Danlou tablet on myocardial ischemia/ reperfusion injury assessed by network pharmacology and experimental verification.
Ye Y; Xiaoyang C; Junkai Y; Yueyao HU; Wei W
J Tradit Chin Med; 2024 Feb; 44(1):131-144. PubMed ID: 38213248
[TBL] [Abstract][Full Text] [Related]
12. Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor.
Zhang Z; Guo Y; Chen M; Chen F; Liu B; Shen C
Inflammopharmacology; 2021 Oct; 29(5):1587-1601. PubMed ID: 34322786
[TBL] [Abstract][Full Text] [Related]
13. Integrated plasma pharmacochemistry and network pharmacology to explore the mechanism of Gerberae Piloselloidis Herba in treatment of allergic asthma.
Zhou K; Lu D; You J; Liu T; Sun J; Lu Y; Pan J; Li Y; Liu C
J Ethnopharmacol; 2022 Nov; 298():115624. PubMed ID: 35970314
[TBL] [Abstract][Full Text] [Related]
14. Network pharmacology and molecular docking-based analyses to predict the potential mechanism of Huangqin decoction in treating colorectal cancer.
Li YJ; Tang DX; Yan HT; Yang B; Yang Z; Long FX
World J Clin Cases; 2023 Jul; 11(19):4553-4566. PubMed ID: 37469733
[TBL] [Abstract][Full Text] [Related]
15. The mechanism of Epimedium in the treatment of coronary atherosclerotic heart disease based on network pharmacology, molecular docking, and in vitro studies.
Xin G; Yuedong Y; Xuemei S; Chenhan M; Meng Z; Chenbo Z; Ning G; Xindong W
Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2478-2488. PubMed ID: 35442463
[TBL] [Abstract][Full Text] [Related]
16. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
17. [Mechanism of Zhongfeng Xingnao Decoction in improving microcirculatory disorders in cerebral hemorrhage based on network pharmacology and molecular docking techniques].
Zhong XQ; Hu DF; Wang Y; Ning ZQ; Deng MZ
Zhongguo Zhong Yao Za Zhi; 2023 Nov; 48(22):6115-6127. PubMed ID: 38114219
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non-small-cell lung cancer: a propensity-matched retrospective study.
Wang X; Zeng Z; Cai J; Xu P; Liang P; Luo Y; Liu A
BMC Cancer; 2021 Apr; 21(1):482. PubMed ID: 33931014
[TBL] [Abstract][Full Text] [Related]
19. Potential Molecular Mechanisms of Ephedra Herb in the Treatment of Nephrotic Syndrome Based on Network Pharmacology and Molecular Docking.
Yao T; Wang Q; Han S; Lu Y; Xu Y; Wang Y
Biomed Res Int; 2022; 2022():9214589. PubMed ID: 35837376
[TBL] [Abstract][Full Text] [Related]
20. Molecular targets and mechanisms of Guanxinning tablet in treating atherosclerosis: Network pharmacology and molecular docking analysis.
Niu C; Zhang P; Zhang L; Lin D; Lai H; Xiao D; Liu Y; Zhuang R; Li M; Ma L; Ye J; Pan Y
Medicine (Baltimore); 2023 Sep; 102(39):e35106. PubMed ID: 37773840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
